Aptevo Therapeutics Inc (APVO) concluded trading on Wednesday at a closing price of $1.38, with 22.97 million shares of worth about $31.7 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -79.26% during that period and on April 03, 2025 the price saw a gain of about 38.26%. Currently the company’s common shares owned by public are about 1.46M shares, out of which, 1.46M shares are available for trading.
Stock saw a price change of -10.39% in past 5 days and over the past one month there was a price change of -53.22%. Year-to-date (YTD), APVO shares are showing a performance of -67.98% which decreased to -99.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.94 but also hit the highest price of $180.19 during that period. The average intraday trading volume for Aptevo Therapeutics Inc shares is 65.64K. The stock is currently trading -34.42% below its 20-day simple moving average (SMA20), while that difference is down -56.04% for SMA50 and it goes to -84.17% lower than SMA200.
Aptevo Therapeutics Inc (NASDAQ: APVO) currently have 1.46M outstanding shares and institutions hold larger chunk of about 3.33% of that.
The stock has a current market capitalization of $2.02M and its 3Y-monthly beta is at 6.00. It has posted earnings per share of -$452.26 in the same period. It has Quick Ratio of 1.72 while making debt-to-equity ratio of 0.97. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APVO, volatility over the week remained 68.15% while standing at 24.73% over the month.
Stock’s fiscal year EPS is expected to rise by 81.87% while it is estimated to increase by 8.52% in next year. EPS is likely to shrink at an annualized rate of 51.40% for next 5-years, compared to annual growth of 80.96% made by the stock over the past 5-years.
Coverage by Piper Jaffray stated Aptevo Therapeutics Inc (APVO) stock as an Overweight in their note to investors on October 05, 2017, suggesting a price target of $6 for the stock.
